<DOC>
	<DOCNO>NCT01997944</DOCNO>
	<brief_summary>This open label study conduct single site China evaluate safety , tolerability PK/PD profile multiple dose recombinant human serum albumin/interferon alpha2a fusion protein chronic hepatitis B patients.The total duration study participation 22 week subject , include 4 week screen period .</brief_summary>
	<brief_title>Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study Chronic Hepatitis B Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Male female , age 1875 year Chronic HBV infection ( serum HBsAg detectable &gt; 6 month ) Serum HBeAg positive HBV DNA &gt; 10^6copies/mL ( &gt; 20,000 IU/mL ) , orSerum HBeAg negative HBV DNA &gt; 10^5copies/mL ( &gt; 2,000 IU/mL ) Serum ALT must &gt; 2 x ULN 10 x ULN Steroid treatment immunosuppression 3 month prior entry . Interferon therapy nucleotide analogues therapy 6 month prior entry . Active lung disease history interstitial lung disease . Hb &lt; LLN , ANC &lt; 750/mm3 , platelet count &lt; 75,000 mm3 , WBC &lt; 3000/mm3 . Significant chronic medical condition chronic hepatitis B opinion investigator preclude enrollment study . Evidence hepatic decompensation ( i.e. , ChildPugh score B C ) . Seropositive HIV , HCV , HDV ( Hepatitis Delta virus ) . History thyroid disease current treatment thyroid disease . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>